Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555297 | 0.85 | NPC1 (0.56) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31602906 | 0.85 | NPC1 (0.56) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14254877 | 0.83 | HTT (0.60) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL458276 | 0.82 | L3MBTL1 (0.48) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10047063 | 0.81 | MAPT (0.52) | LMNANPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL29809375 | 0.81 | HDAC1 (0.63) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3472841 | 0.81 | HDAC1 (0.63) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8365770 | 0.80 | MAPK1 (0.59) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6992137 | 0.80 | KMT2A (0.56) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL64834 | 0.80 | AAK1 (0.53) | LMNANPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1339683-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1418900-A4 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1339683-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040210080-A1 | Selective estrogen receptor modulators | MERCK & CO., INC. | 2004-10-21 | — | — | US | disclosed |
| EP-1418900-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1339683-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003015761-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002041835-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| EP-0755928-B1 | 5-AMINOFLAVONE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2002-04-10 | — | — | EP | disclosed |
| EP-0638566-B1 | 5-Aminoflavone derivatives, their preparation and their use as antibacterial, anti-estrogenic and/or antitumor agent | KYOWA HAKKO KOGYO KK (JP) | 1999-01-07 | — | — | EP | disclosed |
| EP-0755928-A1 | 5-AMINOFLAVONE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-01-29 | — | — | EP | disclosed |
| US-5539112-A | 5-aminoflavone derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0638566-A1 | 5-Aminoflavone derivatives, their preparation and their use as antibacterial, anti-estrogenic and/or antitumor agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | LMNA 3371/4885NPC1 271/4885RAB9A 2944/4885 |
| US-20040210080-A1 | Selective estrogen receptor modulators | GPER1, ESR2, ESR1 | LMNA 1677/4885NPC1 660/4885RAB9A 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.